Neuralstem Announces Issuance of Two U.S. Patents
September 07 2017 - 7:03AM
Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company
developing novel treatments for nervous system diseases, today
announced that it has been awarded two additional patents by the
United States Patent and Trademark Office (USPTO). These
patents broadly protect methods for using neural stem cells to
treat neurodegenerative disorders, a key component of the Company’s
platform.
The first new patent, U.S. Patent No. 9,744,194, covers methods
of treating neurodegenerative disorders through transplantation of
neural stem cells. The second new patent, U.S. Patent No.
9,750,769, covers neural stem cells engineered to express IGF-1, a
neurotrophic molecule with broad therapeutic potential in the
treatment of neurodegenerative disorders.
"We have great confidence in the strength of our intellectual
property, and these new patents provide additional protection for
our platform,” said Rich Daly, Chairman and CEO, Neuralstem.
"Neuralstem now owns or licenses over 20 U.S. and 120 foreign
issued and pending patents, and we continue to pursue more in the
field of regenerative medicine related to our stem cell
technologies and our neurogenic small molecule program.”
About Neuralstem Neuralstem is a clinical-stage
biopharmaceutical company developing novel treatments for nervous
system diseases of high unmet medical need. NSI-189 is a
small molecule in clinical development for major depressive
disorder (MDD) and in preclinical development for Angelman
syndrome, irradiation-induced cognitive impairment, Type 1 and Type
2 diabetes, and stroke.
NSI-566 is a stem cell therapy being tested for treatment of
paralysis in stroke, chronic spinal cord injury (cSCI) and
Amyotrophic Lateral Sclerosis (ALS). Neuralstem’s diversified
portfolio of product candidates is based on its proprietary neural
stem cell technology.
Cautionary Statement Regarding Forward Looking
InformationThis news release contains “forward-looking
statements” made pursuant to the “safe harbor” provisions of the
Private Securities Litigation Reform Act of 1995. Such
forward-looking statements relate to future, not past, events and
may often be identified by words such as “expect,” “anticipate,”
“intend,” “plan,” “believe,” “seek” or “will.” Forward-looking
statements by their nature address matters that are, to different
degrees, uncertain. Specific risks and uncertainties that could
cause our actual results to differ materially from those expressed
in our forward-looking statements include risks inherent in the
development and commercialization of potential products,
uncertainty of clinical trial results or regulatory approvals or
clearances, need for future capital, dependence upon collaborators
and maintenance of our intellectual property rights. Actual results
may differ materially from the results anticipated in these
forward-looking statements. Additional information on potential
factors that could affect our results and other risks and
uncertainties are detailed from time to time in Neuralstem’s
periodic reports, including the Annual Report on Form 10-K for the
year ended December 31, 2016, and Form 10-Q for the three months
ended March 31, 2017, filed with the Securities and Exchange
Commission (SEC), and in other reports filed with the SEC. We do
not assume any obligation to update any forward-looking
statements.
Contact:
Kimberly MinarovichArgot Partners (Investor
Relations)212-600-1902kimberly@argotpartners.com |
|
Lori
RosenLDR Communications (Public
Relations)917-553-6808lori@ldrcommunications.com |
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Neuralstem (NASDAQ:CUR)
Historical Stock Chart
From Sep 2023 to Sep 2024